Related Experiment Videos
Magnesium therapy in acute myocardial infarction
P J Visser1, A C Bredero, J B Hoekstra
1Department of Internal Medicine, Diakonessenhuis Utrecht, Netherlands.
The Netherlands Journal of Medicine
|March 1, 1995
Summary
Intravenous magnesium showed potential in reducing mortality in acute myocardial infarction patients during pre-thrombolytic eras. However, current evidence, including trials with thrombolytic agents, does not support its routine use.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) is a leading cause of mortality.
- Magnesium's role in cardiac health has been investigated for its potential anti-arrhythmic and cardioprotective effects.
Purpose of the Study:
- To evaluate the efficacy of intravenous magnesium in managing arrhythmias and reducing mortality in patients with acute myocardial infarction.
- To synthesize findings from multiple clinical trials conducted in different eras of AMI treatment.
Main Methods:
- Systematic review and meta-analysis of nine pre-thrombolytic era trials investigating intravenous magnesium in AMI.
- Analysis of data from large-scale trials like LIMIT-2 and preliminary results from ISIS-4.
Main Results:
- Magnesium demonstrated a mortality reduction in most reviewed studies, with significant benefits in three trials.
- Meta-analyses of smaller studies indicated a 55% mortality reduction.
- The large LIMIT-2 trial showed a significant 24% reduction in mortality.
- The effect on arrhythmias was less conclusive.
- Preliminary ISIS-4 results, combining magnesium with thrombolytics, did not show a clear benefit.
Conclusions:
- While some trials suggest a mortality benefit of magnesium in AMI, particularly in the pre-thrombolytic era, the overall evidence is mixed.
- Current data, especially from trials involving thrombolytic agents, does not support the routine use of magnesium for acute myocardial infarction.